In this episode, hear Allison Butts, PharmD, BCOP and Danielle Roman, PharmD, BCOP, share their insights on the best practices for incorporating antibody–drug conjugates (ADCs) into clinical practice including:
An overview of ADC structure and mechanism of action
A topline review of data supporting the current FDA-approved indications for ADCs targeting HER2 and TROP-2 across multiple tumor types
An in-depth look at common and serious adverse events with each approved ADC along with an overview of management strategies
Editor’s note: On June 23, 2025, the FDA granted accelerated approval for a new indication for datopotamab deruxtecan, one of the antibody drug conjugates discussed in this podcast. Datopotamab deruxtecan is now also approved for adults with locally advanced or metastatic EGFR-mutated NSCLC who have received previous EGFR-targeted therapy and platinum-based chemotherapy.
Program faculty:
Allison Butts, PharmD, BCOP Pharmacist Manager, Oncology Clinical Pharmacist, Breast Oncology UK HealthCare Markey Cancer Center Lexington, Kentucky
Podden och tillhörande omslagsbild på den här sidan tillhör
ProCE. Innehållet i podden är skapat av ProCE och inte av,
eller tillsammans med, Poddtoppen.
